Efficacy and safety of decompressive craniectomy in acute ischemic stroke patients treated with intravenous thrombolysis. 2023

Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
Neurosciences Research Center (NSRC), Department of Neurology, Imam-Reza hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

BACKGROUND The optimal timing for decompressive hemicraniectomy (DHC) after intravenous thrombolysis (IVT) remains unclear. This study in patients with acute ischemic stroke treated with IVT aimed to assess the safety of DHC and patient outcome. METHODS Data was extracted from the Tabriz stroke registry from June 2011 up to September 2020. In all, 881 patients were treated with IVT. Among these, 23 patients underwent DH. Six patients were excluded due to symptomatic intracranial hemorrhage (parenchymal hematoma type 2 based on SITS-MOST definition) after IVT, but other types of bleeding after venous thrombolysis, including HI1, HI2, and PH1 were not excluded; so the remaining 17 patients were enrolled in the study. Functional Outcome was defined as the proportion of patients who achieved mRS score of 2-3 (moderate disability), 4-5 (severe disability), or 6 (mortality) at 90 days after stroke. mRSwas assess by trained neurologist at the hospital clinic with direct interview Safety outcome was assessed by comparison of two scans just prior to and after craniectomy. Any new hemorrhage or worsening of previous hemorrhage was reported. Parenchymal hematoma type 2, based on ECASS II definition, was considered as major surgical complication. This study was approved by the local ethics committee of the Tabriz University of Medical Sciences (Ethics Code: IR.TBZMED.REC.1398.420). RESULTS At the three-month mRS follow up, six patients (35%) had moderate and five (29%) had severe disability. The outcome of death was observed in six patients (35%).Nine of 15 patients (60%) underwent surgery in the first 48 hours after onset of symptoms. No patient over 60 years of age survived to the three-month follow up; 67% of those who were under60 years and underwent DH in the first 48 hours had favorable outcome. Hemorrhagic complication was seen in 64% of patients but none was major. CONCLUSIONS Results of this study showed that the rate of major bleeding and outcome of acute ischemic stroke patients who underwent DHC after IVT is comparable with the reported data in the literature and intentionally waiting for the fibrinolytic effects of IVT to disappear may not outweigh the benefits of DHC. Although the findings of the study should be interpreted with caution and larger studies are needed to confirm the results.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006406 Hematoma A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue. Hematomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000083242 Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin. Acute Ischemic Stroke,Cryptogenic Embolism Stroke,Cryptogenic Ischemic Stroke,Cryptogenic Stroke,Ischaemic Stroke,Wake-up Stroke,Acute Ischemic Strokes,Cryptogenic Embolism Strokes,Cryptogenic Ischemic Strokes,Cryptogenic Strokes,Embolism Stroke, Cryptogenic,Ischaemic Strokes,Ischemic Stroke, Acute,Ischemic Stroke, Cryptogenic,Ischemic Strokes,Stroke, Acute Ischemic,Stroke, Cryptogenic,Stroke, Cryptogenic Embolism,Stroke, Cryptogenic Ischemic,Stroke, Ischaemic,Stroke, Ischemic,Stroke, Wake-up,Wake up Stroke,Wake-up Strokes
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
June 2019, Critical care (London, England),
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
January 2021, Neurology India,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
August 2013, Annals of neurology,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
October 2021, Neurological research,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
March 2019, Journal of clinical medicine,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
October 2013, International journal of stroke : official journal of the International Stroke Society,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
January 2019, Cerebrovascular diseases (Basel, Switzerland),
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
February 2021, Journal of hypertension,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
June 2021, Journal of the neurological sciences,
Elyar Sadeghi-Hokmabadi, and Farhad Mirzaei, and Mohammad Yazdchi, and Javad Jalili, and Yalda Sadeghpour, and Behzad Nemati-Anari, and Mehdi Farhoudi, and Pouneh HamianRoumiani
April 2006, No to shinkei = Brain and nerve,
Copied contents to your clipboard!